Long-Term Debt: Nanobiotix Corp (NBTX)

Nanobiotix S.A. (NBTX) is developing an innovative system to enhance radiation therapy for tumors, while facing risks of regulatory rejections and a dependence on external financing. This price chart, where the indicator stands at 0.00, links these challenges to management's efforts to secure partners. The company is currently scaling radiosensitization through global alliances, planning to complete the final stages of clinical trials.

NBTX (Nanobiotix Corp) Company Long-Term Debt history from 07/04/2022 to 11/01/2026

Nanobiotix Corp - analytical breakdowns and key metrics (NBTX)

- current quotes and average value forecast:

Stock Quotes nanobiotix.com|NBTX - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Nanobiotix|NBTX - Total Company Value

- book capitalization data:

Net Assets per Single Share Nanobiotix|NBTX - Company Book Value|Market-to-Book Ratio nanobiotix.com|NBTX - Company Total Assets

- debt level and financial liquidity data:

- net income and valuation multiples indicators:

NBTX - Net Profit

Fundamental company valuation:nanobiotix.com

Analyzing the long-term debt dynamics of Nanobiotix S.A. (NBTX), an investor assesses the total volume of credit obligations with a maturity of more than one year. This indicator determines the degree of financial leverage and capital resilience to interest rate risks, which is critical for covering R&D costs and clinical trials of nanopreparations amid regulatory dependence.

Competitors of Nanobiotix S.A. (NBTX)